Search

Para destacar el inicio del Mes de Concientización del Cáncer de Mama, MSK compartió cinco consejos para ayudar a las mujeres a manejar la prevención, el diagnóstico y el tratamiento del cáncer de mama durante la crisis de salud mundial ocasionada por el COVID-19.

… Wednesday, September 30, 2020 Dr. Larry Norton Dr. Larry Norton Para destacar el inicio del Mes de Concientización del Cáncer de Mama, Memorial Sloan Kettering Cancer Center (MSK) compartió cinco consejos para ayudar a las mujeres a manejar la prevención, el diagnóstico y el tratamiento del cáncer de

MSK researchers have found that a protein that contributes to one type of leukemia when it’s missing can lead to the formation of a different leukemia type when it’s present.

… Wednesday, November 21, 2018 Summary MSK researchers have found that Helios — a protein named after the Greek sun god — contributes to one type of leukemia when it’s missing but can lead to the formation of a different leukemia type when it’s present. Proteins are one of the fundamental building blocks

… Wednesday, November 24, 2021 Updates 9/2/25: Dr. Bott, pathologist Marina Baine, MD, PhD , and i nterventional pulmonologist Or Kalchiem-Dekel, MD , recently led the first study to evaluate the yield and accuracy of ssRAB-obtained biopsy specimens across all stages of lung cancer. The retrospective review

Learn how to manage menopause symptoms if you have breast cancer

… Friday, October 28, 2016 Summary The menopause symptoms that can sometimes happen as a result of breast cancer treatment are an unwelcome side effect. Memorial Sloan Kettering medical oncologist Shari Goldfarb shares her recommendations for how women can find relief. Highlights Women with breast cancer

Having two mutated copies of the TP53 gene — as opposed to a single mutated copy — is associated with worse outcomes in a blood cancer called myelodysplastic syndrome, according to a new study led by researchers at Memorial Sloan Kettering.

… Monday, August 3, 2020 Summary A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. Considered the “guardian of the genome,” TP53 is the most commonly

An uptick in colorectal cancer in people under the age of 50 is an alarming trend that led Memorial Sloan Kettering to develop the first of its kind Center for Young Onset Colorectal Cancer in 2018. Read more.

… Monday, August 31, 2020 VIDEO | 01:05 Learn More about MSK's Center for Young Onset Colorectal Cancer Gastroenterologist Robin Mendelsohn explains how young people with colorectal cancer are treated at MSK. She also discusses ongoing research into the causes of young onset colorectal cancer. Video Details

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019. This research is featured in the meeting’s press program, and findings are being presented in the “Next Generation of Clinical Trials in Molecularly Driven Therapy” minisymposium.

… Monday, April 1, 2019 LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food

Learn about the impact of the MSK COVID-19 Fund and The Society 2019–2020 fundraising efforts.

… Thursday, October 1, 2020 The MSK COVID-19 Fund was established in April in response to the desire of so many in our community to help during the crisis. Thanks to more than 3,000 donors, Board members, and MSK employees, the fund has raised more than $6.2 million — making a crucial difference for MSK

For the past five years, we have prospectively evaluated patients with secondary lymphedema of the upper extremity who presented for surgical consultation at Memorial Sloan Kettering Cancer Center (MSK).

… Wednesday, April 8, 2020 For the past five years, we have prospectively evaluated patients with secondary lymphedema of the upper extremity who presented for surgical consultation at Memorial Sloan Kettering Cancer Center (MSK). In our paper, published recently in the journal Cancers , we shared the

The updated versions can survive longer in the body while still packing a punch against cancer.

… Monday, December 17, 2018 Summary Scientists at Memorial Sloan Kettering are learning how to modify the structure of cancer-fighting CAR T cells to boost their performance. Chimeric antigen receptor (CAR) T cells are genetically engineered human immune cells that are designed to fight cancer. They have